The Center for Biosimilars® recaps the top stories for the week of July 15, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 15, 2019.
Number 5: Coherus BioSciences says that, 6 months after launching its biosimilar pegfilgrastim, it has produced more than 400,000 syringes of the product.
Number 4: A rheumatology practice says that using a value-based pathway for rheumatoid arthritis has led to increased biosimilar use.
Number 3: Recent research shows that the Bipartisan Budget Act resulted in a decrease in out-of-pocket spending for biosimilars, but out-of-pocket spending on specialty generics has risen.
Number 2: According to the Congressional Budget Office, enacting the Lower Health Care Costs Act would reduce the deficit by more than 7 billion dollars by 2029.
Number 1: Celltrion announced that it is launching its first clinical trial of biosimilar CT-P39 referencing Xolair. The company plans to commercialize the biosimilar in 2022.
Finally, last week, our e-newsletter asked whether you think that shifting away from buy-and-bill practices for oncology drugs would help reduce costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.